A Randomised Phase 2 Trial of Pemetrexed and Gefitinib Versus Gefitinib as First Line Treatment for Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations

Trial Profile

A Randomised Phase 2 Trial of Pemetrexed and Gefitinib Versus Gefitinib as First Line Treatment for Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 May 2017

At a glance

  • Drugs Pemetrexed (Primary) ; Gefitinib
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 11 Oct 2016 Results of translational research, interim overall survival data and safety data presented at the 41st European Society for Medical Oncology Congress.
    • 09 Aug 2016 Results published in the Journal of Clinical Oncology
    • 28 Apr 2016 Time frame for primary end point has been modified.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top